Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FRANKLIN JOSEPH ZIEVE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1538195060
CMS profile
24562
Location
RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,173.73

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $822.90 3
Food and Beverage $350.00 1
Education $0.83 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk AS $1,172.90 4
Retrophin, Inc. $0.83 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FRANKLIN JOSEPH ZIEVE

NPI 1538195060 · CMS profile ID 24562

Allopathic & Osteopathic Physicians / Internal Medicine

RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538195060?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FRANKLIN JOSEPH ZIEVE, NPI 1538195060, CMS profile ID 24562. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538195060?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). FRANKLIN JOSEPH ZIEVE, NPI 1538195060, CMS profile ID 24562. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538195060?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
FRANKLIN JOSEPH ZIEVE, NPI 1538195060, CMS profile ID 24562, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1538195060?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $1,173.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Retrophin, Inc. $0.8307/10/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701809374 CMS
Novo Nordisk AS $464.0605/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543123 CMS
Novo Nordisk AS $224.8705/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543125 CMS
Novo Nordisk AS $133.9705/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703543127 CMS
Novo Nordisk AS $350.0005/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544555 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,173.73 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $1,927.60 3
PY2023 Principal investigator $3,054.47 9
PY2022 Principal investigator $2,791.18 24
PY2021 Recipient $14.47 1
PY2021 Principal investigator $61,138.24 18
PY2020 Recipient $2,324.14 2
PY2020 Principal investigator $65,973.28 39
PY2019 Principal investigator $201,318.67 62

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Kowa Research Institute, Inc. $1,359.45 12/16/2019 Non-covered Recipient Entity
BOSTON VA RESEARCH INSTITUTE INC
K-877-302 No dispute reported 06/30/2026 629128013
Principal investigator 1 SANOFI US SERVICES INC. $5,564.10 12/11/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691597915
Principal investigator 1 SANOFI US SERVICES INC. $148.00 12/05/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691609709
Principal investigator 1 Kowa Research Institute, Inc. $5,855.80 11/21/2019 Non-covered Recipient Entity
BOSTON VA RESEARCH INSTITUTE INC
K-877-302 No dispute reported 06/30/2026 629128009
Principal investigator 1 SANOFI US SERVICES INC. $1,853.34 11/18/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691599156
Principal investigator 1 SANOFI US SERVICES INC. $955.00 11/05/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691608269
Principal investigator 1 SANOFI US SERVICES INC. $1,853.34 11/04/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691594915
Principal investigator 1 SANOFI US SERVICES INC. $4,614.48 11/04/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691594919
Principal investigator 1 Kowa Research Institute, Inc. $2,855.70 10/25/2019 Non-covered Recipient Entity
BOSTON VA RESEARCH INSTITUTE INC
K-877-302 No dispute reported 06/30/2026 629128007
Principal investigator 1 SANOFI US SERVICES INC. $3,540.75 10/15/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691596533
Principal investigator 1 SANOFI US SERVICES INC. $1,755.42 10/07/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691586421
Principal investigator 1 SANOFI US SERVICES INC. $2,445.96 10/07/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691591311
Principal investigator 1 Kowa Research Institute, Inc. $7,737.75 10/01/2019 Non-covered Recipient Entity
BOSTON VA RESEARCH INSTITUTE INC
K-877-302 No dispute reported 06/30/2026 629128003
Principal investigator 1 SANOFI US SERVICES INC. $4,960.00 09/30/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691571947
Principal investigator 1 Novo Nordisk AS $550.00 09/12/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE INC
EX9536-4388 No dispute reported 06/30/2026 692464291
Principal investigator 1 Novo Nordisk AS $36.00 09/11/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
NN9535-4321 No dispute reported 06/30/2026 706695255
Principal investigator 1 Novo Nordisk AS $9.00 09/11/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
NN9535-4321 No dispute reported 06/30/2026 706695257
Principal investigator 1 Novo Nordisk AS $6.50 09/11/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
NN9535-4321 No dispute reported 06/30/2026 706695259
Principal investigator 1 Novo Nordisk AS $60.00 09/11/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
NN9535-4321 No dispute reported 06/30/2026 706695261
Principal investigator 1 Novo Nordisk AS $9.00 09/11/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
NN9535-4321 No dispute reported 06/30/2026 706695263
Principal investigator 1 Novo Nordisk AS $49.98 09/11/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
NN9535-4321 No dispute reported 06/30/2026 706695265
Principal investigator 1 Novo Nordisk AS $5.30 09/11/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
NN9535-4321 No dispute reported 06/30/2026 706695267
Principal investigator 1 Novo Nordisk AS $2.40 09/11/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
NN9535-4321 No dispute reported 06/30/2026 706695269
Principal investigator 1 Novo Nordisk AS $2.40 09/11/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
NN9535-4321 No dispute reported 06/30/2026 706695271
Principal investigator 1 Novo Nordisk AS $4.99 09/11/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
NN9535-4321 No dispute reported 06/30/2026 706695273
Principal investigator 1 Novo Nordisk AS $4.99 09/11/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
NN9535-4321 No dispute reported 06/30/2026 706695275
Principal investigator 1 Novo Nordisk AS $5.36 09/11/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
NN9535-4321 No dispute reported 06/30/2026 706695277
Principal investigator 1 Novo Nordisk AS $1.08 09/11/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
NN9535-4321 No dispute reported 06/30/2026 706695279
Principal investigator 1 Novo Nordisk AS $3.05 09/11/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
NN9535-4321 No dispute reported 06/30/2026 706695281
Principal investigator 1 SANOFI US SERVICES INC. $1,546.15 08/19/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691592573
Principal investigator 1 SANOFI US SERVICES INC. $955.00 08/12/2019 Non-covered Recipient Entity
Mcguire Research Institute
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691571975
Principal investigator 1 SANOFI US SERVICES INC. $500.00 08/05/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691591461
Principal investigator 1 SANOFI US SERVICES INC. $91.80 08/05/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691594093
Principal investigator 1 Novo Nordisk AS $2,500.00 07/30/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE INC
EX9536-4388 No dispute reported 06/30/2026 692464289
Principal investigator 1 SANOFI US SERVICES INC. $907.80 07/29/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691582171
Principal investigator 1 SANOFI US SERVICES INC. $2,000.90 07/29/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691593683
Principal investigator 1 SANOFI US SERVICES INC. $8,327.28 07/02/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691582541
Principal investigator 1 SANOFI US SERVICES INC. $7,198.65 07/02/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691594031
Principal investigator 1 Novo Nordisk AS $22.97 06/27/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
NN9535-4321 No dispute reported 06/30/2026 706695137
Principal investigator 1 Novo Nordisk AS $1,875.00 06/25/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE INC
EX9536-4388 No dispute reported 06/30/2026 692464287
Principal investigator 1 SANOFI US SERVICES INC. $2,864.00 06/25/2019 Non-covered Recipient Entity
Mcguire Research Institute
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691555990
Principal investigator 1 SANOFI US SERVICES INC. $13,774.08 05/29/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691586959
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 05/23/2019 Non-covered Recipient Entity
Mcguire Research Institute
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691555267
Principal investigator 1 SANOFI US SERVICES INC. $550.00 05/23/2019 Non-covered Recipient Entity
Mcguire Research Institute
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691555403
Principal investigator 1 SANOFI US SERVICES INC. $500.00 05/23/2019 Non-covered Recipient Entity
Mcguire Research Institute
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691555408
Principal investigator 1 Novo Nordisk AS $235.56 05/22/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
EX9536-4388 No dispute reported 06/30/2026 706695141
Principal investigator 1 SANOFI US SERVICES INC. $1,644.24 05/13/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691609797
Principal investigator 1 Kowa Research Institute, Inc. $19,263.00 05/07/2019 Non-covered Recipient Entity
BOSTON VA RESEARCH INSTITUTE INC
K-877-302 No dispute reported 06/30/2026 629127799
Principal investigator 1 SANOFI US SERVICES INC. $2,480.00 04/22/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691574949
Principal investigator 1 SANOFI US SERVICES INC. $8,096.76 04/01/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691573945
Principal investigator 1 SANOFI US SERVICES INC. $112.20 03/25/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691564975
Principal investigator 1 SANOFI US SERVICES INC. $6,683.04 03/25/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691564979
Principal investigator 1 SANOFI US SERVICES INC. $2,401.25 03/25/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691565136
Principal investigator 1 SANOFI US SERVICES INC. $5,153.00 03/21/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691546259
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,416.63 03/05/2019 Non-covered Recipient Entity
Mcguire Research Inst
Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes No dispute reported 06/30/2026 684984461
Principal investigator 1 Novo Nordisk AS $1.70 02/11/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE, INC
EX9536-4388 No dispute reported 06/30/2026 706695139
Principal investigator 1 SANOFI US SERVICES INC. $26,985.12 02/11/2019 Non-covered Recipient Entity
Mcguire Research Inst Inc Research Services 151
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691563381
Principal investigator 1 Kowa Research Institute, Inc. $8,365.00 02/07/2019 Non-covered Recipient Entity
BOSTON VA RESEARCH INSTITUTE INC
K-877-302 No dispute reported 06/30/2026 629127701
Principal investigator 1 AbbVie, Inc. $500.00 02/04/2019 Non-covered Recipient Entity
Mcguire Research Institute Inc
M11-352 No dispute reported 06/30/2026 647580665
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,180.40 02/04/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED EVENT DRIVEN TRIAL OF QUARTERLY SUBCUTANEOUS CANAKINUMAB IN THE PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS AMONG STABLE POST MYOCARDIAL INFARCTION PATIENTS WITH ELEVATED HSCRP No dispute reported 06/30/2026 640719855
Principal investigator 1 Kowa Research Institute, Inc. $6,288.00 01/21/2019 Non-covered Recipient Entity
BOSTON VA RESEARCH INSTITUTE INC
K-877-302 No dispute reported 06/30/2026 629127699
Principal investigator 1 Eli Lilly and Company $4,150.00 01/03/2019 Non-covered Recipient Entity
MCGUIRE RESEARCH INSTITUTE
THE EFFECT OF DULAGLUTIDE ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES - RESEARCHING CARDIOVASCULAR EVENTS WITH A WEEKLY INCRETIN IN DIABETES - REWIND No dispute reported 06/30/2026 654294999